基于证据的数据：不同 PET 放射性药物检测到的甲状腺偶发瘤的患病率和恶性风险。
Evidence-Based Data About Prevalence and Risk of Malignancy of Thyroid Incidentalomas Detected by Different PET Radiopharmaceuticals.
机构信息
School of Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.
Nuclear Medicine, University of Brescia and Spedali Civili of Brescia, Brescia, Italy.
出版信息
Curr Radiopharm. 2020;13(2):89-93. doi: 10.2174/1874471012666191212115732.
BACKGROUND
To date, several meta-analyses and systematic reviews have reported data about the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals.
OBJECTIVE
This article aims to summarize the published evidence-based data about the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals.
METHODS
A comprehensive computer literature search of systematic reviews and meta-analyses published up to July 2019 in PubMed/MEDLINE and Cochrane library databases regarding the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals was carried out.
RESULTS
We have summarized the data about prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals (fluorine-18 fluorodeoxyglucose, radiolabelled choline and prostate-specific membrane antigen) taking into account 8 evidence-based articles.
CONCLUSION
Evidence-based data demonstrated that thyroid incidentalomas detected by different PET radiopharmaceuticals are not infrequent and their risk of malignancy is not negligible, in particular if focal pattern is evident at PET, thus requiring further clinical and instrumental evaluation.
背景
迄今为止，已有多项荟萃分析和系统评价报告了不同 PET 放射性药物检测到的甲状腺偶发瘤的患病率和恶性肿瘤风险的数据。
目的
本文旨在总结不同 PET 放射性药物检测到的甲状腺偶发瘤的患病率和恶性肿瘤风险的已发表循证数据。
方法
对截至 2019 年 7 月在 PubMed/MEDLINE 和 Cochrane 图书馆数据库中发表的关于不同 PET 放射性药物检测到的甲状腺偶发瘤的患病率和恶性肿瘤风险的系统评价和荟萃分析进行全面的计算机文献检索。
结果
我们总结了不同 PET 放射性药物（氟-18 氟代脱氧葡萄糖、放射性标记胆碱和前列腺特异性膜抗原）检测到的甲状腺偶发瘤的患病率和恶性肿瘤风险的数据，共考虑了 8 篇循证文章。
结论
循证数据表明，不同 PET 放射性药物检测到的甲状腺偶发瘤并不少见，其恶性肿瘤风险不容忽视，特别是如果在 PET 上可见局灶性模式，因此需要进一步进行临床和仪器评估。
Zotero 插件